相关实验视频
Updated: May 12, 2026

09:03
Manufacture and Drug Delivery Applications of Silk Nanoparticles
Published on: October 8, 2016
16.0K
无载体的pH响应纳米药物,提供高效的输送和协同治疗
Xuelian Shen1, Mengyun Ge1, Helin Li1
1Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, China.
Langmuir : the ACS journal of surfaces and colloids
|June 30, 2025
概括
这项研究开发了新的无载体纳米药物,使用动态乙烯链接来增强药物输送. 这些系统显示了高药载荷,可控释放和改善的瘤抑制,提供了有希望的癌症治疗方法.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 药物输送系统 药物输送系统
背景情况:
- 传统的纳米载体系统面临着诸如药物负载低,释放控制差,瘤向低效等挑战.
- 开发先进的药物输送系统对于提高治疗疗效和克服传统治疗的局限性至关重要.
研究的目的:
- 为了设计pH响应的,无载体的纳米药物递送系统,利用动态乙烯链接.
- 为了提高药物加载效率,控制药物释放,并使治疗剂的联合递送能够产生协同效应.
- 在癌症模型中评估这些新型纳米药物的治疗潜力.
主要方法:
- 合成修改后的克里佐替尼 (CZT-diol) 来制造用于自组装的两性分子.
- 通过自组装制造的博特佐米布 (BTZ) /CZT-二醇纳米粒子 (BCNP).
- 使用HPLC描述了物理化学性质,药物加载和释放动力学.
- 使用HeLa细胞评估细胞毒性,细胞吸收和3D瘤球状抑制.
主要成果:
- 在BC NPs中实现了97.79%的高BTZ加载效率.
- 在弱酸性条件下释放的药物释放有pH反应,约80%的BTZ和97%的CZT-diol在弱酸性条件下释放.
- 与免费药物相比,BC NPs对HeLa细胞表现出显著的细胞毒性和优异的抑制3D瘤球状生长.
结论:
- 基于动态乙烯链的无载体纳米药物系统为药物输送提供了一种创新的方法.
- 这些系统克服了传统纳米载体的局限性,提供高药物负载,可控释放和增强的治疗结果.
- 开发的纳米药物通过实现高效的代码交付和有针对性的行动,显示出对协同性癌症治疗的巨大潜力.
相关概念视频
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

